Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Modified Release Mesalazine

Mesalazine is a commonly prescribed drug that provides a modified release (MR) delivery of a topical anti-inflammatory for the treatment of Crohn's Disease and Ulcerative Colitis.

Concerns have been raised that there are differences in the release characteristics of the different products. These concerns are based upon in vitro studies of Asacol® and Ipocol®. These differences are the basis of recommendations to prescribed MR mesalazine by brand. However, in vitro differences may not mean that there are clinically noticeable differences.

Both UK Medicines Information and the East Anglian Medicines Information Service have looked at the evidence used to support claims of a difference. They have both concluded that while there is evidence of in vitro differences there is also evidence of clinical similarity based on the available clinical data.

Action: Many MR products should be prescribed by brand but there is currently insufficient clinical data to support brand name prescribing of mesalazine. Generic prescribing should be used in the majority of cases unless individual patients show demonstrable benefit on one product in preference to another.

Share 'Modified Release Mesalazine' on Email Share 'Modified Release Mesalazine' on Delicious Share 'Modified Release Mesalazine' on Digg Share 'Modified Release Mesalazine' on Facebook Share 'Modified Release Mesalazine' on Google+ Share 'Modified Release Mesalazine' on reddit Share 'Modified Release Mesalazine' on StumbleUpon Share 'Modified Release Mesalazine' on Twitter

atomic-wealth

No Comments to “Modified Release Mesalazine”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,657 spam comments.

atomic-wealth
fond-illness
summer